STAT1 negatively regulates hepatocellular carcinoma cell proliferation. 2013

Guofu Chen, and Haihe Wang, and Shuli Xie, and Jian Ma, and Guangyi Wang
Department of General Surgery, the First Hospital of Jilin University, Changchun, Jilin 130021, PR China. guofuch163@163.com

Signal transducer and activator of transcription 1 (STAT1) regulates cell proliferation and survival. The present study aimed to investigate the role of STAT1 in the development and progression of human hepatocellular carcinoma (HCC). The levels of STAT1 expression in 36 HCC and 12 non-HCC liver tissues were examined by immunohistochemistry. The effect of STAT1 overexpression or silencing on the proliferation and apoptosis of HCC cells was determined by MTT and flow cytometric assays. The effect of STAT1 overexpression or silencing on the levels of p53 and cyclin E expression was determined by quantitative PCR and western blot assays. The level of STAT1 expression in the HCC tissues was significantly lower compared to the level in the non-HCC liver tissues and was negatively associated with the histological grade of HCC and serum HBsAg, anti-HCV and α-fetoprotein positivity in HCC patients. Induction of STAT1 overexpression significantly inhibited HepG2 cell proliferation and enhanced HCC cell apoptosis, accompanied by upregulation of p53 expression and STAT1 phosphorylation, but a reduction in cyclin E expression in HepG2 cells. In contrast, knockdown of STAT1 by introduction of STAT1-specific siRNA promoted HepG2 cell proliferation, but inhibited HCC cell apoptosis, accompanied by significant downregulation of p53 expression, but enhancement of cyclin E expression in vitro. Our data suggest that STAT1 may inhibit HCC growth by regulating p53-related cell cycling and apoptosis.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D015870 Gene Expression The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION. Expression, Gene,Expressions, Gene,Gene Expressions
D016159 Tumor Suppressor Protein p53 Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER. p53 Tumor Suppressor Protein,Cellular Tumor Antigen p53,Oncoprotein p53,TP53 Protein,TRP53 Protein,p53 Antigen,pp53 Phosphoprotein,Phosphoprotein, pp53

Related Publications

Guofu Chen, and Haihe Wang, and Shuli Xie, and Jian Ma, and Guangyi Wang
February 2016, Oncology letters,
Guofu Chen, and Haihe Wang, and Shuli Xie, and Jian Ma, and Guangyi Wang
August 2017, Cellular & molecular immunology,
Guofu Chen, and Haihe Wang, and Shuli Xie, and Jian Ma, and Guangyi Wang
December 2019, Medical science monitor : international medical journal of experimental and clinical research,
Guofu Chen, and Haihe Wang, and Shuli Xie, and Jian Ma, and Guangyi Wang
September 2019, Journal of cellular physiology,
Guofu Chen, and Haihe Wang, and Shuli Xie, and Jian Ma, and Guangyi Wang
March 2020, Cell death & disease,
Guofu Chen, and Haihe Wang, and Shuli Xie, and Jian Ma, and Guangyi Wang
January 2017, Molecular and cellular biochemistry,
Guofu Chen, and Haihe Wang, and Shuli Xie, and Jian Ma, and Guangyi Wang
August 2020, BMB reports,
Guofu Chen, and Haihe Wang, and Shuli Xie, and Jian Ma, and Guangyi Wang
March 2017, Oncology letters,
Guofu Chen, and Haihe Wang, and Shuli Xie, and Jian Ma, and Guangyi Wang
March 2014, Oncogene,
Guofu Chen, and Haihe Wang, and Shuli Xie, and Jian Ma, and Guangyi Wang
April 2024, Journal of cellular physiology,
Copied contents to your clipboard!